Atomwise

Atomwise is an AI drug discovery company that uses deep learning and structure-based drug design to identify small molecule drug candidates for challenging therapeutic targets. Its AtomNet neural network predicts binding affinities between small molecules and protein targets by learning from millions of known drug-protein interactions, enabling virtual screening of billions of compounds in days rather than years. Atomwise has formed over 750 research partnerships with pharmaceutical companies and academic institutions to accelerate drug discovery across oncology, infectious disease, and neurodegeneration.